Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Enzymatica appoints Holger Lembrér as CFO
Enzymatica has appointed Holger LembrĂ©r as its new chief financial officer; he will assume the role no later than April 2026 and will be part of the executive management. LembrĂ©r brings extensive CFO experience from listed international companies in medtech, pharma and industry, most recently at Boule Diagnostics and previously at Oncopeptides and ASSA ABLOY. Chairman Bengt Baron highlights LembrĂ©râs financial expertise and international perspective to support the planned international expansion and commercial development. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 644.93k | 13.23% |
| Gross profit | 292.28k | 25.65% |
| Net profit | -1.17m | 9.80% |
| EBITDA | -1.12m | 8.53% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ43.2m |
Number of shares | 242.74m |
52-week high/low | âŹ0.31 - âŹ0.14 |
| Dividends | No |
Beta | -0.38 |
P/E ratio | -10.68 |
PEG ratio | -0.55 |
P/B ratio | 4.89 |
P/S ratio | 9.26 |
Company profile
Enzymatica AB, ein Biowissenschaftsunternehmen, entwickelt und vertreibt Medizinprodukte fĂŒr infektionsbedingte Krankheiten. Zu den Produkten des Unternehmens gehört ColdZyme Mundspray, das ErkĂ€ltungen vorbeugt und die Dauer der Krankheit verkĂŒrzt. AuĂerdem bietet es Enzymformulierungen an. Das Unternehmen vertreibt Mundsprays unter der Marke ViruProtect in DĂ€nemark, STADAProtect in Deutschland, Psysiomer Stop Virus in Frankreich und Zerinol Virus Defense in Italien. Enzymatica AB wurde im Jahr 2007 gegrĂŒndet und hat seinen Hauptsitz in Lund, Schweden.
| Name | Enzymatica AB |
| CEO | Sana Alajmovic |
| Headquarters | Lund,
sn Sweden |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 14/06/2011 |
| Employees | 18 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | ENZY.ST |
Frankfurt | EN9.F |
Stockholm | ENZY.ST |
MĂŒnchen | EN9.MU |
